Evaluating dexamethasone intraocular suspension 9% post-cataract surgery

Conferences|ASCRS

Cathleen McCabe, MD, shares an overview of results from a retrospective study highlighting the effectiveness of dexamethasone intraocular suspension 9% following cataract surgery.

Cathleen McCabe, MD, of The Eye Associates, shares an overview of results from a retrospective study highlighting the effectiveness of dexamethasone intraocular suspension 9% following cataract surgery.

Read the article highlights: Study: Dexamethasone intraocular suspension 9% offering high surgeon, patient satisfaction after cataract surgery

See more ASCRS coverage

Related Videos
Related Content

Evidence-based debates and discussions at COPHy 2023

March 21st 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

iSTAR Medical initiates international STAR-VI trial for the use of its MIGS implant in conjunction with cataract surgery

March 15th 2023

Highlighting results from first FDA-reported study for treatment of presbyopia

September 27th 2021

Harrow announces transitional pass-through reimbursement status for chloroprocaine hydrochloride ophthalmic gel 3%

March 13th 2023

Preoperative OSD: Targeted, efficient screening and therapies for busy practices

February 27th 2023

Evidence-based debates and discussions at COPHy 2023

March 21st 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

iSTAR Medical initiates international STAR-VI trial for the use of its MIGS implant in conjunction with cataract surgery

March 15th 2023

Highlighting results from first FDA-reported study for treatment of presbyopia

September 27th 2021

Harrow announces transitional pass-through reimbursement status for chloroprocaine hydrochloride ophthalmic gel 3%

March 13th 2023

Preoperative OSD: Targeted, efficient screening and therapies for busy practices

February 27th 2023

Evidence-based debates and discussions at COPHy 2023

March 21st 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

iSTAR Medical initiates international STAR-VI trial for the use of its MIGS implant in conjunction with cataract surgery

March 15th 2023

Highlighting results from first FDA-reported study for treatment of presbyopia

September 27th 2021

Harrow announces transitional pass-through reimbursement status for chloroprocaine hydrochloride ophthalmic gel 3%

March 13th 2023

Preoperative OSD: Targeted, efficient screening and therapies for busy practices

February 27th 2023
© 2023 MJH Life Sciences

All rights reserved.